Clinical Trial Search

Primary: Area Under the Concentration-time Curve From 0 to Infinity (AUC 0-∞) Following Single Dose Administration of Famotidine CT Without Water and Famotidine FCT With Water…

Primary: Percentage of Participants With Sustained Virological Response 24 Weeks After Completing Treatment (SVR24) — 83.0 percentage of participants

Primary: Patients With Change in HVPG From Baseline — 1; 1 participants

Primary: Clearance (CL) of Carfilzomib on Day 1 of Cycle 1 — 151; 113; 288; 170 liters/hour — p=0.4114

Primary: Kaplan-Meier Estimate of the Percentage of Patients Who Experienced Cardiovascular Death (CV Death), Myocardial Infarction (MI) or Stroke Within 3 Years From…

Primary: Time to Reach Maximum Observed Plasma Concentration (Tmax) at Steady-State for Both Total and Unbound GDC-0449 — 24; 72; 15; 74 hours

Primary: Percentage of Participants With Tocilizumab Treatment at 6 Months After Treatment Initiation — 73.9 percentage of participants

Primary: Phase 1b: Number of Participants With Dose-limiting Toxicities (DLT) — 0; 0; 1; 0 participants

Primary: Change in Pain Intensity From Baseline to Week 12 — 0.33; 0.46 units on a scale — p=.5870

Primary: Degree of Leakage — 2.6; 4.8; 2.5 units on a scale

Primary: Percentage of Participants With a Best Overall Response (BOR) of Confirmed Complete Response (CR) or Partial Response (PR) — 75.0 percentage of participants

Primary: Geometric Mean Titre (GMT) in Subjects After Receiving One or Two Doses of Either QIVc, TIV1c or TIV2c — 96; 100; NA; 1090 Titers

Primary: Plasma RO5185426 Trough Concentrations on Days 15,16, and 17 — 61.1; 67.7; 61.5 micrograms per milliliter

Primary: The Primary Efficacy Endpoint is Change From Baseline to End of Treatment of Phleum Pratense Specific Immunoglobulin G4 (IgG4) in Serum — 0.684; 0.050 mgA/L

Primary: Number of Subjects With Adverse Events — 175; 82; 20; 6 Subjects